David A. Tess

2.3k total citations
45 papers, 1.1k citations indexed

About

David A. Tess is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, David A. Tess has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 24 papers in Pharmacology and 13 papers in Molecular Biology. Recurrent topics in David A. Tess's work include Drug Transport and Resistance Mechanisms (23 papers), Pharmacogenetics and Drug Metabolism (22 papers) and Computational Drug Discovery Methods (10 papers). David A. Tess is often cited by papers focused on Drug Transport and Resistance Mechanisms (23 papers), Pharmacogenetics and Drug Metabolism (22 papers) and Computational Drug Discovery Methods (10 papers). David A. Tess collaborates with scholars based in United States, Australia and India. David A. Tess's co-authors include Tristan S. Maurer, Dennis O. Scott, Manthena V. S. Varma, Li Di, Sangwoo Ryu, Sumathy Mathialagan, John Litchfield, Jian Lin, Bo Feng and Michael C. Linhares and has published in prestigious journals such as Nature Communications, Journal of Medicinal Chemistry and European Heart Journal.

In The Last Decade

David A. Tess

44 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Tess United States	18	477	365	296	229	146	45	1.1k
Cho‐Ming Loi United States	23	615 1.3×	611 1.7×	691 2.3×	153 0.7×	117 0.8×	44	1.7k
Bill J. Smith United States	20	697 1.5×	348 1.0×	467 1.6×	327 1.4×	158 1.1×	28	1.6k
Ajay Madan United States	20	366 0.8×	561 1.5×	364 1.2×	80 0.3×	83 0.6×	62	1.6k
Stephen Fowler Switzerland	22	314 0.7×	560 1.5×	321 1.1×	111 0.5×	149 1.0×	47	1.1k
Nina Hanke Germany	20	193 0.4×	308 0.8×	299 1.0×	158 0.7×	70 0.5×	40	1.1k
Toshiyuki Kume Japan	20	393 0.8×	434 1.2×	223 0.8×	233 1.0×	40 0.3×	41	858
Satoru Asahi Japan	16	449 0.9×	455 1.2×	382 1.3×	188 0.8×	79 0.5×	52	1.3k
Birk Poller Switzerland	20	684 1.4×	254 0.7×	337 1.1×	257 1.1×	67 0.5×	35	1.3k
Jocelyn Yabut United States	16	471 1.0×	314 0.9×	357 1.2×	273 1.2×	35 0.2×	19	1.3k
Ernesto Callegari United States	15	342 0.7×	396 1.1×	421 1.4×	158 0.7×	187 1.3×	29	1.3k

Countries citing papers authored by David A. Tess

Since Specialization

Citations

This map shows the geographic impact of David A. Tess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Tess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Tess more than expected).

Fields of papers citing papers by David A. Tess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Tess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Tess. The network helps show where David A. Tess may publish in the future.

Co-authorship network of co-authors of David A. Tess

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Tess. A scholar is included among the top collaborators of David A. Tess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Tess. David A. Tess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Rui, et al.. (2024). Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors. Clinical Pharmacokinetics. 63(8). 1177–1189. 2 indexed citations

Adair, Brian D., Conroy O. Field, José Luís Izquierdo Alonso, et al.. (2024). Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model. Nature Communications. 15(1). 8612–8612. 5 indexed citations

Tess, David A., et al.. (2024). Prediction of Drug-Drug Interactions for Highly Plasma Protein Bound Compounds. The AAPS Journal. 27(1). 13–13. 1 indexed citations

Rajan, Shiny Amala Priya, Jason Sherfey, Lauren M. Nichols, et al.. (2023). A Novel Milli-fluidic Liver Tissue Chip with Continuous Recirculation for Predictive Pharmacokinetics Applications. The AAPS Journal. 25(6). 102–102. 17 indexed citations

Tess, David A., George Chang, Christopher Keefer, et al.. (2023). In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance of Human and Preclinical Species with Liver Microsomes and Hepatocytes. The AAPS Journal. 25(3). 40–40. 26 indexed citations

Qiu, Ruolun, Kari R. Fonseca, Arthur Bergman, et al.. (2023). Study of the ketohexokinase inhibitor PF‐06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and Translational Science. 17(1). e13644–e13644. 1 indexed citations

Weng, Yan, Kari R. Fonseca, Yi‐An Bi, et al.. (2022). Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition. 50(9). 1312–1321. 6 indexed citations

Tess, David A., Sangwoo Ryu, & Li Di. (2022). In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species. Pharmaceutical Research. 39(7). 1615–1632. 17 indexed citations

Tseng, Elaine, Heather Eng, Jian Lin, et al.. (2021). Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes. Drug Metabolism and Disposition. 49(10). 947–960. 27 indexed citations

10.

Eng, Heather, Yi‐An Bi, Mark A. West, et al.. (2021). Organic Anion–Transporting Polypeptide 1B1/1B3–Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro–In Vivo Evaluation in Cynomolgus Monkey. Journal of Pharmacology and Experimental Therapeutics. 377(1). 169–180. 15 indexed citations

11.

Tess, David A., Heather Eng, Amit S. Kalgutkar, et al.. (2020). Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs. Journal of Medicinal Chemistry. 63(20). 11831–11844. 15 indexed citations

12.

Riccardi, Keith, Sangwoo Ryu, David A. Tess, et al.. (2020). Comparison of Fraction Unbound Between Liver Homogenate and Hepatocytes at 4°C. The AAPS Journal. 22(4). 91–91. 10 indexed citations

13.

Orozco, Christine C., Karen Atkinson, Sangwoo Ryu, et al.. (2019). Structural attributes influencing unbound tissue distribution. European Journal of Medicinal Chemistry. 185. 111813–111813. 21 indexed citations

14.

Riccardi, Keith, David A. Tess, Jian Lin, et al.. (2019). A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Medated Mechanisms Using Suspended Human Hepatocytes. Drug Metabolism and Disposition. 47(5). 484–492. 32 indexed citations

15.

Bi, Yi‐An, Chester Costales, Sumathy Mathialagan, et al.. (2019). Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: “SLC-Phenotyping” Using Primary Human Hepatocytes. Journal of Pharmacology and Experimental Therapeutics. 370(1). 72–83. 66 indexed citations

16.

Riccardi, Keith, Sangwoo Ryu, Jian Lin, et al.. (2018). Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines. Drug Metabolism and Disposition. 46(4). 415–421. 34 indexed citations

17.

Kimoto, Emi, Sumathy Mathialagan, Laurie Tylaska, et al.. (2018). Organic Anion Transporter 2–Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability–Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. Journal of Pharmacology and Experimental Therapeutics. 367(2). 322–334. 46 indexed citations

18.

Bandara, Nilantha, Alex Zheleznyak, David A. Griffith, et al.. (2015). Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging. Molecular Imaging and Biology. 18(1). 90–98. 13 indexed citations

19.

Robinson, Ralph P., Jeremy A. Bartlett, Peter Bertinato, et al.. (2011). Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide. Bioorganic & Medicinal Chemistry Letters. 21(14). 4150–4154. 10 indexed citations

20.

Lafontaine, Jennifer, John R. Hadcock, Diane M. Hargrove, et al.. (2007). Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity. Bioorganic & Medicinal Chemistry Letters. 17(18). 5245–5250. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact